Literature DB >> 33899112

Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro.

Maxim A X Tollenaere1, Thomas Litman, Lena Moebus, Elke Rodriguez, Dora Stölzl, Katharina Drerup, Thomas Werfel, Jochen Schmitt, Hanne Norsgaard, Stephan Weidinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33899112      PMCID： PMC9364260          DOI： 10.2340/00015555-3810

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  10 in total

Review 1.  Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis.

Authors:  Thomas Bieber
Journal:  Allergy       Date:  2019-07-15       Impact factor: 13.146

2.  Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.

Authors:  Emma Guttman-Yassky; Robert Bissonnette; Benjamin Ungar; Mayte Suárez-Fariñas; Marius Ardeleanu; Hitokazu Esaki; Maria Suprun; Yeriel Estrada; Hui Xu; Xiangyu Peng; Jonathan I Silverberg; Alan Menter; James G Krueger; Rick Zhang; Usman Chaudhry; Brian Swanson; Neil M H Graham; Gianluca Pirozzi; George D Yancopoulos; Jennifer D D Hamilton
Journal:  J Allergy Clin Immunol       Date:  2018-09-05       Impact factor: 10.793

3.  Efficacy of biologics in atopic dermatitis.

Authors:  Jianni Wu; Emma Guttman-Yassky
Journal:  Expert Opin Biol Ther       Date:  2020-02-03       Impact factor: 4.388

4.  Atopic dermatitis displays stable and dynamic skin transcriptome signatures.

Authors:  Lena Möbus; Elke Rodriguez; Inken Harder; Dora Stölzl; Nicole Boraczynski; Sascha Gerdes; Andreas Kleinheinz; Susanne Abraham; Annice Heratizadeh; Christiane Handrick; Eva Haufe; Thomas Werfel; Jochen Schmitt; Stephan Weidinger
Journal:  J Allergy Clin Immunol       Date:  2020-06-29       Impact factor: 10.793

Review 5.  Atopic dermatitis.

Authors:  Sinéad M Langan; Alan D Irvine; Stephan Weidinger
Journal:  Lancet       Date:  2020-08-01       Impact factor: 79.321

6.  Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses.

Authors:  Lam C Tsoi; Elke Rodriguez; Dora Stölzl; Ulrike Wehkamp; Jingru Sun; Sascha Gerdes; Mrinal K Sarkar; Matthias Hübenthal; Chang Zeng; Ranjitha Uppala; Xianying Xing; Frederieke Thielking; Allison C Billi; William R Swindell; Alanna Shefler; Jiahan Chen; Matthew T Patrick; Paul W Harms; J Michelle Kahlenberg; Bethany E Perez White; Emanual Maverakis; Johann E Gudjonsson; Stephan Weidinger
Journal:  J Allergy Clin Immunol       Date:  2019-12-28       Impact factor: 10.793

7.  The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature.

Authors:  Ana B Pavel; Lisa Zhou; Aisleen Diaz; Benjamin Ungar; Joshua Dan; Helen He; Yeriel D Estrada; Hui Xu; Marie Fernandes; Yael Renert-Yuval; James G Krueger; Emma Guttman-Yassky
Journal:  J Am Acad Dermatol       Date:  2019-10-25       Impact factor: 11.527

8.  Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis.

Authors:  Lam C Tsoi; Elke Rodriguez; Frauke Degenhardt; Hansjörg Baurecht; Ulrike Wehkamp; Natalie Volks; Silke Szymczak; William R Swindell; Mrinal K Sarkar; Kalpana Raja; Shuai Shao; Matthew Patrick; Yilin Gao; Ranjitha Uppala; Bethany E Perez White; Spiro Getsios; Paul W Harms; Emanual Maverakis; James T Elder; Andre Franke; Johann E Gudjonsson; Stephan Weidinger
Journal:  J Invest Dermatol       Date:  2019-01-11       Impact factor: 7.590

9.  Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

Authors:  A Wollenberg; A Blauvelt; E Guttman-Yassky; M Worm; C Lynde; J-P Lacour; L Spelman; N Katoh; H Saeki; Y Poulin; A Lesiak; L Kircik; S H Cho; P Herranz; M J Cork; K Peris; L A Steffensen; B Bang; A Kuznetsova; T N Jensen; M L Østerdal; E L Simpson
Journal:  Br J Dermatol       Date:  2020-12-30       Impact factor: 9.302

10.  Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.

Authors:  J I Silverberg; D Toth; T Bieber; A F Alexis; B E Elewski; A E Pink; D Hijnen; T N Jensen; B Bang; C K Olsen; A Kurbasic; S Weidinger
Journal:  Br J Dermatol       Date:  2021-02-22       Impact factor: 9.302
  10 in total
  1 in total

Review 1.  Tralokinumab: First Approval.

Authors:  Sean Duggan
Journal:  Drugs       Date:  2021-09       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.